Immunotherapy for Cancer Insurance Claim Denied? How to Appeal

Cancer immunotherapy — including checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, atezolizumab/Tecentriq), CAR-T cell therapies (axicabtagene ciloleucel/Yescarta, lisocabtagene maraleucel/Breyanzi), and cancer vaccines — represents the most significant advance in oncology in decades. These treatments cost $100,000–$500,000 or more per course and are among the most frequently denied cancer treatments. When your insurer denies immunotherapy, an effective appeal requires NCCN guideline citations, FDA approval documentation, and evidence of the treatment's proven survival benefit.

Why Insurers Deny Cancer Immunotherapy

Experimental or investigational classification. Despite FDA approval and NCCN Category 1 recommendations for many checkpoint inhibitors, insurers sometimes still classify immunotherapy as experimental — particularly for newer indications or tumor-agnostic approvals. This classification is directly challengeable with FDA approval documentation and current NCCN Guideline versions.

Biomarker requirement not met. Checkpoint inhibitors for certain cancers require biomarker testing — PD-L1 expression, tumor mutational burden (TMB), or MSI-H/dMMR status — to qualify for coverage. Denials citing "biomarker criteria not met" require either documentation that the biomarker was tested and qualifies, or an argument that the tumor-agnostic FDA approval applies regardless of biomarker status.

Prior treatment step therapy. Some plans require failure of chemotherapy before approving immunotherapy as first-line treatment, even when NCCN guidelines recommend immunotherapy upfront for certain cancers (e.g., pembrolizumab for PD-L1 high non-small cell lung cancer, or first-line combination therapy for melanoma).

CAR-T cell therapy denied as experimental. FDA-approved CAR-T therapies for relapsed/refractory large B-cell lymphoma, ALL, multiple myeloma, and mantle cell lymphoma have NCCN Category 1 recommendations. Denial as "experimental" is factually incorrect and challengeable.

Off-label use. Immunotherapy is increasingly used for tumor-agnostic indications based on biomarker profiles rather than tumor type. The FDA's tumor-agnostic approvals for pembrolizumab (MSI-H/TMB-H) and dostarlimab cover this use, and NCCN guidelines support it.

Not medically necessary. The insurer's reviewer applies criteria that do not reflect current oncology guidelines or the patient's specific biomarker profile and disease stage.

How to Appeal a Cancer Immunotherapy Denial

Step 1: Request expedited review immediately

Cancer treatment denials must be appealed on an expedited basis. Under federal ERISA and ACA regulations, when standard timelines would seriously jeopardize your health, you are entitled to a decision within 72 hours for internal appeals and 72 hours for External Independent Review: Complete Guide" class="auto-link">external review. Your oncologist should certify the urgency in writing.

Step 2: Compile FDA approval and NCCN guideline documentation

Obtain the current version of the relevant NCCN Guideline showing the specific recommendation and category level for your cancer type and stage. Download the FDA approval history for the specific immunotherapy agent and indication. For tumor-agnostic indications, the FDA's product label and NCCN framework for tumor-agnostic treatment are essential.

Step 3: Document biomarker testing results

If the denial cites biomarker criteria, compile all biomarker testing results — PD-L1 immunohistochemistry (percentage and clone used), TMB testing results (mutations/Mb), MSI testing (PCR or IHC), or HER2/NTRK/ALK/ROS1/EGFR/KRAS status. If the denial argues your biomarker doesn't qualify, your oncologist should explain why the testing meets the standard criteria.

Step 4: Obtain your oncologist's comprehensive letter

The letter must cite: FDA approval for the specific indication, NCCN Guideline recommendation (category level), clinical trial data demonstrating survival benefit (e.g., KEYNOTE trials for pembrolizumab, CheckMate trials for nivolumab), your specific biomarker results, and why this treatment is medically necessary for your specific case at this disease stage.

Step 5: File internal appeal and request peer-to-peer review

Submit the formal appeal with all documentation and request an expedited peer-to-peer review between your oncologist and the insurer's medical director. Many immunotherapy denials are resolved at peer-to-peer when the oncologist can directly explain the biomarker-driven treatment rationale.

Step 6: Escalate to external review

If the internal appeal fails, file for independent external review by an oncologist. NCCN Category 1 recommendations with FDA approval carry extremely high persuasive force at the external review level. File a simultaneous complaint with your state department of insurance.

What to Include in Your Appeal

• FDA approval letter or product label for the specific immunotherapy and indication
• Current NCCN Guideline page showing the recommendation and category level (Category 1 is strongest)
• Biomarker testing results — PD-L1, TMB, MSI, and any tumor-specific markers used to select the therapy
• Oncologist letter citing landmark trials (KEYNOTE, CheckMate, CHECKMATE, IMpower series) demonstrating survival benefit
• Disease staging documentation — imaging, pathology confirming stage and histology
• Prior treatment history for step therapy disputes

Fight Back With ClaimBack

Cancer immunotherapy denials require appeals grounded in FDA approvals, NCCN guidelines, and biomarker documentation. ClaimBack generates a targeted oncology appeal in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal